ArticleFrontiers in oncology2025
Advancing breast cancer relapse prediction with radiomics and neural networks: a clinically interpretable framework.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence for triple-negative breast cancer from imaging to multi-omics.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early assessment of breast cancer relapse can significantly impact survival rates and overall oncological outcomes, highlighting the need to use sophisticated diagnostic strategies in clinical trials. This work utilizes clinically relevant radiomic features extracted from digital mammograms to develop a deep learning-based model for forecasting breast cancer relapse. Features, including tumor size, shape, margin characteristics, molecular subtype, and breast density, were systematically extracted from our private, in-house dataset, providing a comprehensive representation of intrinsic tumor properties and assisting in relapse prediction. The predictive model demonstrated outstanding performance with an average area under the curve (AUC) of 0.957, highlighting its effectiveness in identifying possible relapse. This approach not only underscores the abilities of radiomics in enhancing the granularity of tumor assessment but also assists in identifying cancer recurrence during the treatment stage, promising significant strides toward personalized cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.